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Effectiveness of probiotics in reducing Necrotizing Enterocolitis 
(NEC) severity in preterm or low birth weight infants: A review of 
the literature 
abstract 
BACKGROUND AND OBJECTIVE:  Necrotizing enterocolitis (NEC) is a 
debilitating and often deadly bowel disease affecting premature and low 
birth weight neonates. Probiotics may be useful in decreasing incidence 
and severity of NEC. Our objective was to review the most recent 
literature on the use of probiotics to reduce NEC severity in preterm 
and/or low birth weight neonates. 
METHODS:  A PubMed search using keyword “NEC, necrotizing 
enterocolitis, probiotic*” was conducted. Studies were considered if at 
least one probiotic was used in an attempt to reduce NEC incidence or 
severity in preterm or low birth weight infants. Original studies from 
2012-2014 were considered. Meta-analyses and summary articles were 
excluded. 
RESULTS:  Ten studies met inclusion criteria. Four found statistically 
significant results in the reduction of incidence of NEC in neonates, one 
found a protective effect against the need for NEC surgery, and five 
studies found no benefit in preventing NEC.  
CONCLUSIONS:  Of the six randomized controlled trials included in this 
study, only two found a statistically significant reduction in NEC 
incidence. Although the efficacy is unclear, all ten studies did support the 
safety of probiotics administration. Further research utilizing specific 
promising probiotic strains, including Bifidobacterium infantis and 
Lactobacillus rhamnosus, should be carried out to continue determining 
efficacy of these strains.   
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Necrotizing enterocolitis (NEC) 
is one of the most devastating 
complications endured by 
hospitalized infants. NEC is an 
ischemic bowel disease, often 
manifesting initially as 
abdominal distention and 
bloody stools, and progressing 
as far as bowel resection or even 
death. The exact etiology of NEC 
is unknown. The incidence and 
prevalence of NEC varies based 
on location worldwide, race, 
birth weight, and gestational 
age. Low birth weight and 
premature infants are more 
likely to be affected by NEC. 1 
Estimates of NEC incidence in 
the United States fall around 
0.1% of all births, with risk of 
NEC varying from 3-12% of very 
low birth weight (<1500 grams) 
infants, with highest risk in the 
lowest birth weight category of 
501-750 grams. 2 3 4  Much 
research has been done in the 
last quarter-century in an 
attempt to gain knowledge 
surrounding this deadly illness. 
Animal models have given 
insight into potential 
mechanisms of the ischemia, 
while human studies have 
provided breakthroughs on 
clinical prevalence and 
management. Because of the 
devastating outcomes of 
developing NEC, research into 
prevention strategies is a high 
priority. Some prophylactic 
measures, such as exclusive 
human milk feedings, are well 
accepted in practice; while 
others, such as the use of 
probiotics to assist in preventing 
NEC, are more contested.  
Although the exact etiology of 
NEC is unknown, it is generally 
accepted that the 
pathophysiology of the disease 
is a complex mix of various 
influencing factors. It is not as 
well known how factors such as 
the type, amount, and diversity 
of microorganisms in the gut of 
infants contributes to the 
development of NEC. However, 
prematurity, mucosal injury, 
inflammatory response, 
bacterial translocation, bacterial 
overgrowth, low gut bacteria 
species diversity, and the 
presence of potential 
pathogenic organisms are 
thought to potentially 
contribute.5 6 7 8 9 10 
Because the exact etiology is still 
unknown, treatment of NEC is 
general, supportive care. 
Typically, patients who are 
exhibiting clinical symptoms of 
NEC are made NPO (nil per os, 
nothing by mouth) for bowel 
rest and undergo a ~14 day 
course of broad spectrum 
antibiotics to mediate the bowel 
ischemia and infection. This 
bowel rest can further lengthen 
the amount of time it takes to 
reach full enteral feedings, 
lengthening hospital stays and 
increasing costs of care.  
Because of the devastating 
burden NEC brings to 
individuals, families, and health 
care systems, there is great 
interest in discussing strategies 
to prevent its occurrence. One 
such strategy is the 
administration of probiotics. 
Probiotics are live 
microorganisms, such as 
bacteria, that are hypothesized 
to be beneficial in assisting with 
the prevention of NEC in 
neonates. An infant with a gut 
microbiome that is void of the 
‘beneficial’ bacteria or low in 
bacterial diversity may be at an 
increased risk for NEC. By adding 
these ‘beneficial’ bacteria, they 
may outcompete the 
‘pathogenic’ bacteria, promote 
a stronger gut wall structure to 
prevent mucosal injury, and 
assist in promoting a positive 
immune response for the infant. 
Probiotics are relatively 
accessible and inexpensive.  
Not all probiotics are created 
equal. Some strains are more 
widely tested in the use of NEC 
prevention. Each probiotic strain 
has different properties and 
may behave in differing ways in 
the gut. Gram-positive 
microorganisms such as 
Lactobacilli and Bifidobacteria 
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are thought to be beneficial in 
balancing out the coliforms 
typically found in a preterm 
newborn’s gut.11  
There have been a number of 
studies reported on the use of 
probiotics to prevent NEC in the 
past decade. This analysis 
focuses on the most recent 
studies, published from January 
2012 to August 2014, to provide 
a brief summary of the most 
current work in the field of 
probiotic use to prevent NEC.  
METHODS 
A review of the literature was 
performed using PubMed 
database by searching “NEC, 
probiotic*, necrotizing 
enterocolitis”. Studies published 
from 2012-2014 with risk of NEC 
as at least one outcome of study 
were included. Only original 
studies were utilized. Review 
articles and meta-analyses were 
not included.  
RESULTS 
Of the search results, 10 studies 
were found to meet inclusion 
criteria. Four of these were 
classified as cohort studies, 
while the remaining six were 
randomized trials. The majority 
of the studies (n=7) were 
conducted outside of the United 
States. A variety of different 
protocols were used 
throughout, including varying 
probiotic strains, dosages, and 
initiation and duration 
timelines. Sample sizes ranged 
from a prospective randomized 
controlled trial of 101 infants to 
5351 infants in one 
observational cohort study.  
A double-blind, randomized 
controlled trial was conducted in 
13 NICUs from Italy and New 
Zealand.12 A total of 743 very 
low birth weight infants were 
randomized to receive bovine 
lactoferrin (BLF) + Lactobacillus 
rhamnosus GG (LGG) (6 x 109 
colony forming units/day) or 
bovine lactoferrin alone (100 
mg/day) or placebo. Animal 
studies had shown a beneficial 
effect of lactoferrin on reducing 
NEC, and LGG is thought to 
increase the efficacy of 
lactoferrin, although this had 
not previously been studied in a 
human model. The findings 
showcased a significantly lower 
incidence of NEC in the BLF and 
BLF+LGG groups vs. control (BLF 
+ LGG vs. control: RR 0.00 
(p<0.001)). The incidence of 
death and/or NEC was also 
significantly reduced in both the 
BLF and BLF+LGG groups vs. 
control (BLF + LGG vs. control: 
RR = 0.37 (0.18-0.77) p=0.006). 
Although the incidence of NEC 
was significantly lower in the 
intervention groups, no direct 
comparisons were made 
between the two treatment 
groups. Therefore, it remains 
unclear whether the BLF or LGG 
was contributing to decreased 
NEC rates, although since both 
BLF + LGG and BLF alone saw 
reduced NEC incidence, it is 
likely that the probiotic LGG was 
not the critical intervention 
ingredient.  
A second double-blind, 
randomized controlled trial 
included 1099 infants from 
hospitals in Australia and New 
Zealand.13 A 1.5 gram powder 
probiotic combination of 
Bifidobacterium infantis, 
Streptococcus thermophilis and 
Bifidobacterium lactis was 
administered daily to infants 
<1500 grams birth weight and 
younger than 32 completed 
weeks gestational age who were 
randomized to the intervention 
group until discharged or term 
corrected age. The group found 
a reduced incidence ≥ stage 2 
NEC in the intervention group 
(2% vs 4.4%, RR = 0.46, 95% CI 
0.23-0.93, p=0.03).  
A retrospective cohort study 
from the United States found 
similarly positive results.14 
Hunter et al. compared infants 
who were born before a 
departmental protocol change 
of introduction of 0.1 ml of the 
probiotic Lactobacillus reuteri 
with those infants born after 
protocol change who weighed 
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≤1000 grams at birth. The 
incidence of NEC was 
significantly lower in the 
neonates given probiotics 
versus the controls (2.5% versus 
15.1%, p=0.0475). No adverse 
events related to probiotic use 
were noted.  
A Canadian prospective cohort 
study by Janvier et al. studied 
whether routine administration 
of a 0.5 gram probiotic mixture 
(Bifidobacterium breve, 
Bifidobacterium bifidum, 
Bifidobacterium infantis, 
Bifidobacterium longum, and 
Lactobaciluus rhamnosus GG) 
would reduce the incidence of 
NEC.15 All infants before 48 
hours of age and <32 weeks 
gestational age received 
probiotics beginning in August 
2011, from the first feed until 
the infant reached 34 weeks 
gestational age. Study 
participants admitted prior to 
August 2011 served as the 
control group. After adjusting 
for confounding factors such as 
gestational age, intrauterine 
growth restriction, and gender, 
a significant reduction in NEC 
was found in the probiotics 
group (OR 0.51, 95% CI 0.26-
0.98). There was no effect of 
probiotics on health care-
associated infection. However, it 
is notable that when stratified to 
only infants <1001 grams birth 
weight, all results were non-
significant, including reduction 
in NEC between groups. In 
addition, the proportion of NEC 
within the first two weeks of life, 
‘early cases’, was increased in 
the probiotic group, although 
not significantly. Overall, this 
study did find a reduced 
frequency in NEC in this NICU 
with use of a probiotic mixture. 
In Germany, Hartel et al. 
conducted an observational 
cohort study using 5351 infants 
divided into three groups based 
on probiotic use in the facility 
caring for the infant: 1) no 
prophylactic probiotic use in the 
facility, 2) facility change of 
probiotic nonuser to user during 
observational period, or 3) 
probiotic use currently in 
facility.16 Lactobacillus 
acidophilus and Bifidobacterium 
infantis were used, however the 
dosages and inclusion criteria 
differed between centers. Most 
centers administered 1 capsule 
once per day of probiotics and 
included infants with birth 
weight <1500 grams, although 
some restricted to <1000 grams. 
The use of probiotics was found 
to be protective against NEC 
surgery (OR 0.58, 95% CI 0.37-
0.91).  
A prospective, randomized 
controlled trial from Turkey 
found that 100 million colony 
forming units per day (5 drops) 
of Lactobacillus reuteri (DSM 
17938) did not produce a 
statistically significant 
difference in frequency of NEC in 
400 very low birth weight infants 
born at or before 32 weeks 
gestation (RR 1.4; 95% CI 0.76-
2.59, p=0.27).17 However, 
probiotic supplementation was 
found to significantly reduce the 
frequency of culture-proven 
sepsis (RR 2.05; 95% CI 1.01-
4.14, p=0.041) and rates of 
feeding intolerance in this 
sample (intervention group 28% 
vs. placebo group 39.5%, 
p=0.015). Duration of 
hospitalization was also 
significantly lower in the 
probiotic group (38 vs. 46 days, 
p=0.022). None of the positive 
blood cultures grew L.reuteri 
and no other adverse events 
were attributed to L.reuteri 
administration.  
Serce et al. orchestrated a 
placebo controlled trial from 
Turkey of 208 infants ≤32 weeks 
gestational age and weighing 
≤1500 grams at birth.18 These 
newborns were supplemented 
with Saccharomyces boulardii 
dosed at 50 mg/kg every 12 
hours, starting with the first 
feeding until discharged. It is 
notable that the rate of NEC in 
this hospital NICU prior to this 
study was 17%, higher than the 
average rate. The authors found 
no statistically significant 
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differences between the 
intervention and control group 
for NEC rate.    
In the United States, Al-Hosni et 
al. conducted a double-blind, 
randomized controlled trial with  
101 premature infants with birth 
weight 501-1000 grams who 
were ≤14 days old at time of 
feeding initiation.19 The 
intervention group was given a 
combination of Lactobacillus 
rhamnosus GG and 
Bifidobacterium infantis (500 
colony forming units) added 
once daily to 0.5 ml of their first 
enteral feeding and continued 
until discharge or 34 weeks 
gestational age. Although the 
primary outcome of this study 
was infant weight, the 
incidences of NEC and mortality 
were similar between the 
intervention and control groups.  
Another double-blind, 
randomized controlled trial was 
performed by Fernandez-
Carrocera et al. in 150 preterm 
newborns weighing <1500 g at 
birth in Mexico.11 The 
intervention group was given 1 
gram per day of a combination 
probiotic including Lactobacillus 
acidophilus, Lactobacillus 
rhamnosus, Lactobacillus casei, 
Lactobacillus plantarum, 
Bifidobacterium infantis, and 
Streptococcus thermophillus 
administered from the first day 
they started enteral feedings. 
Control participants were given 
regular feedings with no 
probiotics added. The authors 
found no significant difference 
in the risk of developing NEC 
between groups (8% vs 16% in 
control, p=0.132), and no 
significant difference in 
mortality between groups. 
However, when the risk of 
mortality or NEC was combined, 
fewer infants in the probiotic 
group died or developed NEC 
(RR 0.39, 95% CI 0.17-0.87).  
A retrospective cohort study 
from the United States by Li et 
al. analyzed charts to determine 
if a three-strain probiotic blend 
of Streptococcus thermophiles, 
Bifidobacterium infantis, and 
Bifidobacterium bifidum had an 
effect on morbidity and 
mortality of NEC.20 Infants who 
weighed <1500 grams at birth 
and received ≥ 5 days of feeding 
or probiotics were analyzed. The 
incidence and mortality of NEC 
was similar between the two 
groups. The severity of NEC was 
higher in the probiotics group 
(2.13 vs. 2.57, p=0.075). It is 
notable that the probiotics 
group did have a statistically 
lower average gestational age 
than the control group; lower 
gestational age is a known NEC 
risk factor.   
 
CONCLUSIONS 
Effectiveness of probiotics in 
assisting to prevent NEC 
Among the ten studies collected 
for this analysis, four found 
statistically significant results in 
the reduction of incidence of 
NEC in neonate, one found a 
protective effect against the 
need for NEC surgery, and five 
studies did not conclude any 
significant findings (Table 1). Of 
the randomized controlled 
trials, viewed as the ‘gold-
standard’ of research in this 
field, two found statistically 
significant results and four did 
not. 
Ideal gestational age or birth 
weight for intervention 
 Inclusion criteria varied among 
the five studies with statistically 
significant findings. The majority 
of these studies used birth 
weight of <1500 grams and 
gestational age of <32 or <33 
weeks to determine study 
participants. However, Janvier 
et al. found a loss of significance 
in the reduction of NEC for 
neonates <1001 when their 
results were stratified by infant 
birth weight.15 Thus, from this 
analysis, <32-33 weeks 
gestational age and birth weight 
of 1000-1500 grams appears to 
be the ideal inclusion criteria for 
use of probiotics to reduce NEC 
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incidence or severity in 
premature infants. 
Most effective probiotics 
Summarizing findings from 
studies that use probiotics in an 
attempt to prevent NEC can be 
challenging due to the variety of 
probiotics that are 
administered. Within these ten 
studies, 12 different probiotics 
were used. It is difficult to 
determine whether individual 
probiotics are more effective, or 
if probiotics have a more 
profound effect when working 
in combination with other 
probiotics. Among the five 
studies that found significantly 
reduced NEC incidence or risk, 
Bifidobacterium infantis and 
Lactobacillus rhamnosus were 
the most common strains. Four 
of these studies used 
combination probiotics, while 
one study used just a single 
strain.  
Safety of probiotics 
No adverse events related to the 
use of probiotics were found in 
any of the studies included in 
this analysis. In fact, many of the 
studies found other positive 
results from probiotic use not 
related to NEC. Janvier et al. 
found that the duration of 
intravenous nutrition was 
significantly shorter in the 
probiotic period of their cohort 
study.15 The randomized 
controlled trial by Al-Hosni et al. 
found a higher calculated 
growth velocity in their probiotic 
intervention group, which is an 
especially important parameter 
in premature infants.19 A second 
randomized controlled trial 
found the time to reach full 
enteral feedings and the 
duration of hospitalization were 
significantly lower in their 
probiotic intervention group.  
Overall, half of the studies in this 
analysis found promising 
reductions in incidence or 
severity of NEC in premature 
neonates. However, of the six 
randomized controlled trials, 
only two found positive results. 
Importantly, no adverse events 
were found in any of the studies 
related to probiotic 
administration. Additionally, 
other benefits of probiotics 
were identified without any 
harmful side effects. The 
administration of probiotics in 
neonates <33 weeks gestational 
age and 1001-1500 grams birth 
weight is a safe strategy to assist 
in preventing NEC.  
LIMITATIONS AND FUTURE 
DIRECTIONS 
While this review does provide 
important insights into the most 
recent evidence on the use of 
probiotics to assist in NEC 
prevention, some important 
limitations should be 
considered. This review only 
included studies from January 
2012 – August 2014 and was 
unable to pool data into a meta-
analysis. Further research into 
the use of probiotics to assist in 
preventing NEC is warranted. 
While important to note that the 
administration of probiotics 
appears to be safe, the efficacy 
of probiotics in general is not 
clear. The studies in this field 
contain a diverse array of 
probiotic strains, inclusion 
criteria, administration amounts 
and methods, and duration 
times. To maximize resources, 
additional studies comparing 
the promising strains of 
Bifidobacterium infantis and 
Lactobacillus rhamnosus 
identified in this analysis, should 
be performed. Varying inclusion 
criteria should continue, and 
analyses should be stratified 
according to gestational age and 
weight to continue to narrow 
the neonatal population that 
may most benefit from the use 
of probiotics to assist in the 
prevention of NEC.  
*Note: In September 2014, after 
beginning this review paper, a 
Cochrane review was published 
that analyzed randomized 
controlled trials from several 
databases from 1966 to 2013. 
This review found evidence to 
support using probiotics to 
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reduce occurrence of NEC in 
premature infants with birth 
weight less than 1500 grams, 
while evidence for effectiveness 
in infants with birth weight less 
than 1000 grams is not 
conclusive.  
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 TABLE 1    Articles published January 2012 - August 2014 focused on probiotic use to reduce incidence or severity of NEC in preterm and/or low birth weight neonates 
Authors Study design Subjects Probiotic used Significantly reduced NEC incidence or 
severity? 
Al-Hosni et al. 
2012 
USA 
RCT N=101 
501-1000g  
 
 Lactobacillus rhamnosus GG + Bifidobacterium 
infantis 
No 
Incidence of NEC similar between 
groups 
Fernandez-Carrocera et al. 
2013 
Mexico 
RCT N=150 
<1500 g 
Lactobacillus acidophilus + Lactobacillus casei + 
Lactobacillus planatarum + Bifidobacterium 
infantis + Streptococcus thermophillus  
No 
Incidence of developing NEC similar 
between groups 
 
*Hartel et al. 
2014 
Germany 
Retrospective  
cohort 
N=5351 
<1500 g 
>22+6 and <32+0 GA 
Lactobacillus acidophilus + Bifidobacterium 
infantis 
Yes 
Protective for NEC surgery 
*Hunter et al. 
2012 
USA 
Retrospective  
cohort 
N=311 
(79 probiotic, 232 comparison) 
≤1000 g 
Lactobacillus reuteri DSM 17938 Yes 
Reduced incidence of NEC 
*Jacobs et al. 
2013 
Australia/New Zealand 
RCT N=1099 
<1500 g 
<33 weeks GA 
Bifidobacterium infantis + Streptococcus 
thermophils + Bifidobacterium lactis 
Yes 
Reduced incidence of NEC 
*Janvier et al. 
2014 
Canada 
Prospective  
cohort 
N=611 
(294 probiotic, 317 comparison) 
<32 weeks GA 
Lactobacillus rhamnosus GG  + 4 types 
Bifidobacterium: breve, bifidum, infantis, longum 
Yes 
Reduced incidence of NEC (when 
unstratified for weight) 
Li et al. 
2013 
USA 
Retrospective  
cohort 
N=580 
(291 probiotic, 289 comparison) 
<1500 g 
Streptococcus thermophiles + Bifidobacterium 
infantis + Bifidobacterium bifidum 
No 
Incidence and mortality of NEC similar 
between groups 
*Manzoni et al. 
2014 
Italy/New Zealand 
RCT N=743 
<1500 g 
 
Bovine Lactoferrin ± Lactobacillus rhamnosus GG Yes 
Incidence of NEC significantly lower 
Oncel et al. 
2014 
Turkey 
RCT N=400 
≤1500 g 
≤32 weeks GA 
Lactobacillus reuteri DSM 17938 No 
Incidence of NEC similar between 
groups 
Serce et al. 
2013 
Turkey 
RCT N=208 
≤1500 g 
≤32 weeks GA 
Saccharomyces boulardii No 
Incidence of NEC similar between 
groups 
